(c) 2024 PillSync.com

atomoxetine capsule

1 INDICATIONS AND USAGE Atomoxetine capsules are a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1) 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14) ] . 1.2 Diagnostic Considerations A diagnosis of ADHD (DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. The specific etiology of ADHD is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV characteristics. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming, leaving seat, inappropriate running/climbing, difficulty with quiet activities, “on the go,†excessive talking, blurting answers, can’t wait turn, intrusive. For a Combined Type diagnosis, both inattentive and hyperactive-impulsive criteria must be met. 1.3 Need for Comprehensive Treatment Program Atomoxetine capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms.

Aurobindo Pharma Limited


4 years ago CAPSULE BLUE F 46 atomoxetine capsule

CAPSULE BLUE F 46

4 years ago CAPSULE BLUE F 46 atomoxetine capsule

F 46 CAPSULE BLUE

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied

ATOMOXETINE capsules USP, 10 mg* are off-white opaque/off-white opaque, size ‘5’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on off-white opaque cap & ‘41’ on off-white opaque body with black ink. Bottles of 30 NDC 65862-238-30 Bottles of 2,000 NDC 65862-238-22

ATOMOXETINE capsules USP, 18 mg* are golden opaque/off-white opaque, size ‘4’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on golden opaque cap & ‘42’ on off-white opaque body with black ink. Bottles of 30 NDC 65862-239-30 Bottles of 2,000 NDC 65862-239-22

ATOMOXETINE capsules USP, 25 mg* are blue opaque/off-white opaque, size ‘4’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on blue opaque cap & ‘43’ on off-white opaque body with black ink. Bottles of 30 NDC 65862-240-30 Bottles of 2,000 NDC 65862-240-22

ATOMOXETINE capsules USP, 40 mg* are blue opaque/blue opaque, size ‘2’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on blue opaque cap & ‘45’ on blue opaque body with black ink. Bottles of 30 NDC 65862-241-30 Bottles of 1,000 NDC 65862-241-99

ATOMOXETINE capsules USP, 60 mg* are blue opaque/golden opaque, size ‘1’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on blue opaque cap & ‘46’ on golden opaque body with black ink. Bottles of 30 NDC 65862-242-30 Bottles of 1,000 NDC 65862-242-99

ATOMOXETINE capsules USP, 80 mg* are brown opaque/off-white opaque, size ‘0’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘F’ on brown opaque cap & ‘47’ on off-white opaque body with black ink. Bottles of 30 NDC 65862-243-30 Bottles of 500 NDC 65862-243-05

ATOMOXETINE capsules USP, 100 mg* are brown opaque/brown opaque, size ‘0EL’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘Y’ on brown opaque cap & ‘04’ on brown opaque body with black ink. Bottles of 30 NDC 65862-244-30 Bottles of 500 NDC 65862-244-05 *

ATOMOXETINE base equivalent. 16.2 Storage and Handling Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [see USP Controlled Room Temperature].


More pills like CAPSULE F 46

Related Pills

atomoxetine 80 mg

Aurobindo Pharma Limited

atomoxetine 10 mg

Aurobindo Pharma Limited

atomoxetine 100 mg

Aurobindo Pharma Limited

atomoxetine 40 MG Oral Capsule

aurobindo pharma limited

atomoxetine capsule

aurobindo pharma limited

atomoxetine capsule

aurobindo pharma limited












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site